Skip to main content

Buy Out Soon?

Do we really have a two year wait? 

My guess is we do not. I believe that big pharma is watching, they understand the science and the gold mine that this company is sitting on. They are not going to wait two years, as they would miss the boat. This is going up for sale in 6 to 12 months.

Hang on to your shares for dear life.

TC.



Comments

  1. I'd guess that the eventual market correction will not have too adverse an effect on our sp as the predators are doing a great job of keeping it suppressed artificially anyway. That of course works in our favor as well as some of us undoubtedly continue to accumulate shares along with the institutional and hedge fund investors who control the price for now. This stock has become boring to the point of not needing to keep track constantly of events which are few and far between, quite different from our previous investment. I am hoping, but not necessarily expecting, a surge in the sp upon announcement of the next indication for Voclosporin in the fall. If nothing else that should provide more reassurance as to why we are spending two or three years of our time and money invested in this company. The biggest obstacle here to achieving wealth is the difficulty of waiting patiently, which for me at least, has never been easy.

    ReplyDelete
    Replies
    1. Yes, waiting patiently is the hardest part, and this is absolutely a boring stock to watch. That said, I really don't miss the Ariad drama...not to mention the complete idiocy of LieHub.

      Delete
    2. TC, any idea what a possible or probable war with North Korea will do to the markets in general and the biotech sector in particular? My guess is that a war will be the trigger for a market correction of significant proportion but will have little effect on small biotechs like AUPH which are not dependent on sales at this point.

      Delete
    3. Well it will certainly not be good!

      Delete
  2. Wondering if the predators can get this down to low 5's or under. There is tremendous opportunity for those of us here who understand the process, perhaps much better than Ariad and in a much shorter time frame.

    ReplyDelete
  3. iHub is just toooooo funny. People are talking to the troll BR like he's a real person. Complete idiocy, can't believe otherwise intelligent people are getting sucked into that. Hilarious!!

    ReplyDelete
  4. I would be much more concerned if there were not paid bashers like BR trying to get weak longs to sell. His employers want every cheap share that they can get. As a matter of fact, so do I, and I will continue to be a buyer if the sp is pushed down lower. If not, I'm very happy with my current position which is larger than the share count I had in Ariad. Just wish it wasn't so boring waiting for this win.

    ReplyDelete
  5. Vid I have the same concerns about what happens to the market in a time of war. TC, can you elaborate? I know going to war in general is not good for the market, but what will it mean specifically for AUPH? I'm sure nobody really knows that answer, but if we truly are in a waiting game for at least a couple of years then should we really not be concerned? It's the only thing making me considering pulling some shares back.

    ReplyDelete
  6. I think we have a 30/70 chance of a war with N Korea. We will certainly win and I think after an initial knee jerk market correction, that a war with North Korea will result in a continuation of the long bull market. Or the beginning of another bull run after a short lived bear market. It should have a very minimal and transient effect on our SP, an opportunity to add more shares.

    ReplyDelete
  7. Just read BR's "butt ugly" post and was wondering if he was finally revealing some personal information.

    ReplyDelete
  8. Hope you folks took advantage of the 5's to add more. As we approach the announcement of the next indication there will probably be few, if any, opportunities to add cheap shares. Glad I waited.

    ReplyDelete
  9. I would like to see Trump do the right thing and call out these asshole white supremacists for what they are, the scum of the earth.

    ReplyDelete
  10. Loved BR's comment tonight about the "unknown solder". I think this is his way of bonding with the rest of us.

    ReplyDelete
  11. For all of us long suffering longs, in the words of that great investor BR: "solder on"!

    ReplyDelete
  12. I think a 20-40 percent market correction could see us temporarily in the low 4's or high 3's. I have set aside a substantial amount for more shares if that occurs which would be an incredible gift to knowledgeable investors. Eventually we will very likely see 35-60's or higher depending on how events unfold.

    ReplyDelete
  13. I will also have to load up if that happens. I do imagine this goes up with the news coming this fall, so the correction would have to happen before that and I personally don't see that happening. Summer coming to an end should mean more volume and more interest back in the market in general.

    ReplyDelete
  14. Once again, tonight BR attempts to confuse the distinction between SLE and LN, stating he is "not so sure of the potential for a blockbuster drug", failing to add that he was referring to treatment for Lupus in general, not Lupus Nephritis for which a blockbuster drug now exists and will be approved fairly soon: Voclosporin. A subtle, if fairly weak, attempt at discouraging retailers. But that is understandable, it is his job to post this garbage. Thankfully, he isnt good at it.

    ReplyDelete
  15. BR and his same old tired bag of tricks. You like how I called him out yesterday to bring forward a legitimate negative claim on Auph, and nothing but silence...

    ReplyDelete
  16. Right, he of course had no reply to your post. Tonight he posts completely false information regarding the kidney foundation's position on lupus nephritis. Posting false information which sounds authoritative is right out of the basher handbook. If someone does challenge it they will be met with silence just as your post was. Too bad the asshole isn't posting on this forum. I would love the opportunity to be able to deal with him without the nazi censorship of the Ihub board.

    ReplyDelete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient pool (US, Europe, Japan): 252,333  % of patients on treatment: 50%  To

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that the applicant stud

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)